Potential of coconut oil and medium chain triglycerides in the prevention and treatment of Alzheimer's disease.
Level 5 - mechanism / opinion, no new human data
Narrative review of mechanistic hypotheses and literature without systematic methodology
PubMed 31953123 · doi:10.1016/j.mad.2020.111209
What was done
This narrative review summarizes proposed metabolic mechanisms and existing literature regarding the role of coconut oil and medium-chain fatty acids in Alzheimer's disease prevention and treatment.
What was found
No numerical results or primary clinical outcomes are reported in the abstract. The authors describe the biological rationale that medium-chain fatty acids travel directly to the liver to produce ketone bodies, potentially serving as an alternative energy source for glucose-hypometabolic brain tissue, and discuss reported neuroprotective, antioxidant, and anti-inflammatory effects.
Why it matters
It outlines the metabolic hypothesis for using dietary medium-chain triglycerides as an alternative energy substrate in neurodegenerative diseases with impaired glucose utilization.
Limits
As a narrative review, it presents no primary clinical data, quantitative effect estimates, or systematic synthesis. Human efficacy, optimal dosing, and clinical outcomes remain unmeasured in the abstract.
Cited by
- supports Medium-chain triglycerides travel directly to the liver and are metabolized and burned off more readily than long-chain triglycerides.